



Molecular Mechanisms and Clinical Implications of Pancreatic Cancer

Guest Editor:

Dr. Koichi Suzuki

Department of Surgery, Saitama
Medical Center, Jichi Medical
University, 1-847 Amanuma-cho,
Omiya-ku, Saitama-shi, Saitama
330-8503, Japan

Deadline for manuscript
submissions:

1 September 2024

Message from the Guest Editor

Dear Colleagues,

Pancreatic cancer is one of the most lethal malignancies. Despite significant progress in other cancers, pancreatic cancer survival rates have remained relatively unchanged for 40 years. New approaches are critical to successfully diagnosing and treating this disease.

Due to the recent progress in comprehensive analysis using next-generation sequencing, we have deeply understood the molecular characteristics of pancreatic cancer, including genetic and epigenetic alterations. These alterations are potent biomarkers for diagnosis and predicting therapeutic outcomes for pancreatic cancer patients. The real-time monitoring of these alterations is realized by the use of liquid biopsy and has been implemented into clinical practice.

This Special Issue focuses on the biomarkers underlying the molecular biology of pancreatic cancer and discusses how to implicate them into clinical practice. Original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Koichi Suzuki
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI